{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T23:37:45Z","timestamp":1790206665825,"version":"4.1.0"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2024,5,2]],"date-time":"2024-05-02T00:00:00Z","timestamp":1714608000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2024,5,2]],"date-time":"2024-05-02T00:00:00Z","timestamp":1714608000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100014943","name":"Sarepta Therapeutics","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100014943","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Adv Ther"],"published-print":{"date-parts":[[2024,6]]},"DOI":"10.1007\/s12325-024-02865-2","type":"journal-article","created":{"date-parts":[[2024,5,2]],"date-time":"2024-05-02T17:01:58Z","timestamp":1714669318000},"page":"2519-2530","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Observing the Clinical Course of Duchenne Muscular Dystrophy in Medicaid Real-World Healthcare Data"],"prefix":"10.1007","volume":"41","author":[{"given":"Christina","family":"Qian","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexa C.","family":"Klimchak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9044-3192","authenticated-orcid":false,"given":"Shelagh M.","family":"Szabo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Evan","family":"Popoff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan T.","family":"Iannaccone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katherine L.","family":"Gooch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,5,2]]},"reference":[{"issue":"1","key":"2865_CR1","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1002\/mus.23807","volume":"48","author":"CM McDonald","year":"2013","unstructured":"McDonald CM, Henricson EK, Abresch RT, et al. The cooperative international neuromuscular research group Duchenne natural history study\u2014a longitudinal investigation in the era of glucocorticoid therapy: design of protocol and the methods used. Muscle Nerve. 2013;48(1):32\u201354.","journal-title":"Muscle Nerve"},{"key":"2865_CR2","unstructured":"Parent Project Muscular Dystrophy. The Duchenne Registry 2019. https:\/\/www.duchenneregistry.org\/. Accessed 24 Apr 2024."},{"key":"2865_CR3","unstructured":"Centers for Disease Control and Prevention. Muscular Dystrophy Research and Tracking, 2019. https:\/\/www.cdc.gov\/ncbddd\/musculardystrophy\/research.html. Accessed 24 Apr 2024."},{"issue":"12","key":"2865_CR4","doi-asserted-by":"publisher","first-page":"1048","DOI":"10.1212\/WNL.0000000000001950","volume":"85","author":"L Bello","year":"2015","unstructured":"Bello L, Gordish-Dressman H, Morgenroth LP, et al. Prednisone\/prednisolone and deflazacort regimens in the CINRG Duchenne Natural History Study. Neurology. 2015;85(12):1048\u201355.","journal-title":"Neurology"},{"issue":"8","key":"2865_CR5","doi-asserted-by":"publisher","first-page":"730","DOI":"10.1016\/j.nmd.2017.05.019","volume":"27","author":"S Kim","year":"2017","unstructured":"Kim S, Zhu Y, Romitti PA, et al. Associations between timing of corticosteroid treatment initiation and clinical outcomes in Duchenne muscular dystrophy. Neuromuscul Disord. 2017;27(8):730\u20137.","journal-title":"Neuromuscul Disord"},{"issue":"5","key":"2865_CR6","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1177\/0883073816687422","volume":"32","author":"M McKane","year":"2017","unstructured":"McKane M, Soslow JH, Xu M, et al. Does body mass index predict premature cardiomyopathy onset for Duchenne muscular dystrophy? J Child Neurol. 2017;32(5):499\u2013504.","journal-title":"J Child Neurol"},{"issue":"4","key":"2865_CR7","doi-asserted-by":"publisher","first-page":"1080","DOI":"10.1016\/j.jpeds.2013.05.060","volume":"163","author":"BJ Barber","year":"2013","unstructured":"Barber BJ, Andrews JG, Lu Z, et al. Oral corticosteroids and onset of cardiomyopathy in Duchenne muscular dystrophy. J Pediatr. 2013;163(4):1080\u20134.","journal-title":"J Pediatr"},{"issue":"10119","key":"2865_CR8","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1016\/S0140-6736(17)32160-8","volume":"391","author":"CM McDonald","year":"2018","unstructured":"McDonald CM, Henricson EK, Abresch RT, et al. Long-term effects of glucocorticoids on function, quality of life, and survival in patients with Duchenne muscular dystrophy: a prospective cohort study. Lancet. 2018;391(10119):451\u201361.","journal-title":"Lancet"},{"issue":"2","key":"2865_CR9","first-page":"117","volume":"31","author":"S Rall","year":"2012","unstructured":"Rall S, Grimm T. Survival in Duchenne muscular dystrophy. Acta Myol. 2012;31(2):117\u201320.","journal-title":"Acta Myol"},{"issue":"2","key":"2865_CR10","first-page":"121","volume":"31","author":"L Passamano","year":"2012","unstructured":"Passamano L, Taglia A, Palladino A, et al. Improvement of survival in Duchenne muscular dystrophy: retrospective analysis of 835 patients. Acta Myol. 2012;31(2):121.","journal-title":"Acta Myol"},{"issue":"12","key":"2865_CR11","doi-asserted-by":"publisher","first-page":"2191","DOI":"10.1164\/ajrccm.164.12.2103052","volume":"164","author":"MF Phillips","year":"2001","unstructured":"Phillips MF, Quinlivan RC, Edwards RH, Calverley PM. Changes in spirometry over time as a prognostic marker in patients with Duchenne muscular dystrophy. Am J Respir Crit Care Med. 2001;164(12):2191\u20134.","journal-title":"Am J Respir Crit Care Med"},{"key":"2865_CR12","doi-asserted-by":"publisher","DOI":"10.3233\/JND-220816","author":"SM Szabo","year":"2022","unstructured":"Szabo SM, Klimchak AC, Qian C, Iannaccone S, Popoff E, Gooch KL. Characterizing the occurrence of key clinical milestones in Duchenne muscular dystrophy in the United States using real-world data. J Neuromuscul Dis. 2022. https:\/\/doi.org\/10.3233\/JND-220816.","journal-title":"J Neuromuscul Dis"},{"issue":"10","key":"2865_CR13","first-page":"1426","volume":"27","author":"AC Klimchak","year":"2021","unstructured":"Klimchak AC, Szabo SM, Qian C, Popoff E, Iannaccone S, Gooch KL. Characterizing demographics, comorbidities, and costs of care among populations with Duchenne muscular dystrophy with Medicaid and commercial coverage. J Manag Care Spec Pharm. 2021;27(10):1426\u201337.","journal-title":"J Manag Care Spec Pharm"},{"issue":"1","key":"2865_CR14","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1186\/s13023-021-01862-w","volume":"16","author":"SM Szabo","year":"2021","unstructured":"Szabo SM, Salhany RM, Deighton A, Harwood M, Mah J, Gooch KL. The clinical course of Duchenne muscular dystrophy in the corticosteroid treatment era: a systematic literature review. Orphanet J Rare Dis. 2021;16(1):237.","journal-title":"Orphanet J Rare Dis"},{"issue":"6","key":"2865_CR15","doi-asserted-by":"publisher","first-page":"2906","DOI":"10.1007\/s12325-022-02117-1","volume":"39","author":"J Iff","year":"2022","unstructured":"Iff J, Zhong Y, Gupta D, et al. Disease progression stages and burden in patients with Duchenne muscular dystrophy using administrative claims supplemented by electronic medical records. Adv Ther. 2022;39(6):2906\u201319.","journal-title":"Adv Ther"},{"issue":"10","key":"2865_CR16","doi-asserted-by":"publisher","first-page":"1275","DOI":"10.1177\/0883073814558120","volume":"30","author":"S Kim","year":"2015","unstructured":"Kim S, Campbell KA, Fox DJ, Matthews DJ, Valdez R, STARnet MD. Corticosteroid treatments in males with duchenne muscular Dystrophy: treatment duration and time to loss of ambulation. J Child Neurol. 2015;30(10):1275\u201380.","journal-title":"J Child Neurol"},{"issue":"19","key":"2865_CR17","doi-asserted-by":"publisher","first-page":"1607","DOI":"10.1212\/01.wnl.0000260974.41514.83","volume":"68","author":"W King","year":"2007","unstructured":"King W, Ruttencutter R, Nagaraja HN, et al. Orthopedic outcomes of long-term daily corticosteroid treatment in Duchenne muscular dystrophy. Neurology. 2007;68(19):1607\u201313.","journal-title":"Neurology"},{"issue":"2","key":"2865_CR18","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1002\/mus.26129","volume":"58","author":"S Pandya","year":"2018","unstructured":"Pandya S, James KA, Westfield C, et al. Health profile of a cohort of adults with Duchenne muscular dystrophy. Muscle Nerve. 2018;58(2):219\u201323.","journal-title":"Muscle Nerve"},{"issue":"4","key":"2865_CR19","doi-asserted-by":"publisher","first-page":"S122","DOI":"10.1016\/j.healun.2018.01.290","volume":"37","author":"K Gambetta","year":"2018","unstructured":"Gambetta K, Wittlieb-Weber C, Bock M, et al. Impact of genotype on boys with Duchenne muscular dystrophy. J Heart Lung Transplant. 2018;37(4):S122.","journal-title":"J Heart Lung Transplant"},{"issue":"4","key":"2865_CR20","doi-asserted-by":"publisher","first-page":"293","DOI":"10.3233\/JND-170280","volume":"4","author":"Z Koeks","year":"2017","unstructured":"Koeks Z, Bladen CL, Salgado D, et al. Clinical outcomes in Duchenne muscular dystrophy: a study of 5345 patients from the TREAT-NMD DMD global database. J Neuromuscul Dis. 2017;4(4):293\u2013306.","journal-title":"J Neuromuscul Dis"},{"issue":"11","key":"2865_CR21","doi-asserted-by":"publisher","first-page":"897","DOI":"10.1016\/j.nmd.2018.07.004","volume":"28","author":"CM McDonald","year":"2018","unstructured":"McDonald CM, Gordish-Dressman H, Henricson EK, et al. Longitudinal pulmonary function testing outcome measures in Duchenne muscular dystrophy: Long-term natural history with and without glucocorticoids. Neuromuscul Disord. 2018;28(11):897\u2013909.","journal-title":"Neuromuscul Disord"},{"issue":"4","key":"2865_CR22","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1212\/WNL.0000000000002891","volume":"87","author":"L Bello","year":"2016","unstructured":"Bello L, Morgenroth LP, Gordish-Dressman H, et al. DMD genotypes and loss of ambulation in the CINRG Duchenne Natural History Study. Neurology. 2016;87(4):401\u20139.","journal-title":"Neurology"},{"issue":"3","key":"2865_CR23","doi-asserted-by":"publisher","first-page":"488","DOI":"10.1016\/j.ejpn.2017.12.004","volume":"22","author":"RGF Hendriksen","year":"2018","unstructured":"Hendriksen RGF, Vles JSH, Aalbers MW, Chin RFM, Hendriksen JGM. Brain-related comorbidities in boys and men with Duchenne muscular dystrophy: a descriptive study. Eur J Paediatr Neurol. 2018;22(3):488\u201397.","journal-title":"Eur J Paediatr Neurol"},{"issue":"1","key":"2865_CR24","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1111\/dmcn.12922","volume":"58","author":"V Ricotti","year":"2016","unstructured":"Ricotti V, Mandy WP, Scoto M, et al. Neurodevelopmental, emotional, and behavioural problems in Duchenne muscular dystrophy in relation to underlying dystrophin gene mutations. Dev Med Child Neurol. 2016;58(1):77\u201384.","journal-title":"Dev Med Child Neurol"},{"issue":"6","key":"2865_CR25","first-page":"633","volume":"23","author":"S Thayer","year":"2017","unstructured":"Thayer S, Bell C, McDonald CM. The direct cost of managing a rare disease: assessing medical and pharmacy costs associated with Duchenne muscular dystrophy in the United States. J Manag Care Spec Pharm. 2017;23(6):633\u201341.","journal-title":"J Manag Care Spec Pharm"},{"issue":"3","key":"2865_CR26","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1002\/mus.23942","volume":"49","author":"J Larkindale","year":"2014","unstructured":"Larkindale J, Yang W, Hogan PF, et al. Cost of illness for neuromuscular diseases in the United States. Muscle Nerve. 2014;49(3):431\u20138.","journal-title":"Muscle Nerve"},{"issue":"15","key":"2865_CR27","doi-asserted-by":"publisher","first-page":"1456","DOI":"10.1001\/jama.2022.4315","volume":"327","author":"M Guglieri","year":"2022","unstructured":"Guglieri M, Bushby K, McDermott MP, et al. Effect of different corticosteroid dosing regimens on clinical outcomes in boys with Duchenne muscular dystrophy: a randomized clinical trial. JAMA. 2022;327(15):1456\u201368.","journal-title":"JAMA"},{"issue":"296\u2013303","key":"2865_CR28","volume":"182","author":"BL Wong","year":"2017","unstructured":"Wong BL, Rybalsky I, Shellenbarger KC, et al. Long-term outcome of interdisciplinary management of patients with Duchenne muscular dystrophy receiving daily glucocorticoid treatment. J Pediatr. 2017;182(296\u2013303): e1.","journal-title":"J Pediatr"},{"issue":"4","key":"2865_CR29","doi-asserted-by":"publisher","first-page":"1606","DOI":"10.1016\/j.chest.2020.04.043","volume":"158","author":"F Trucco","year":"2020","unstructured":"Trucco F, Domingos JP, Tay CG, et al. Cardiorespiratory progression over 5\u00a0years and role of corticosteroids in Duchenne muscular dystrophy: a single-site retrospective longitudinal study. Chest. 2020;158(4):1606\u201316.","journal-title":"Chest"}],"container-title":["Advances in Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-024-02865-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12325-024-02865-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-024-02865-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,28]],"date-time":"2024-05-28T13:25:15Z","timestamp":1716902715000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12325-024-02865-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5,2]]},"references-count":29,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2024,6]]}},"alternative-id":["2865"],"URL":"https:\/\/doi.org\/10.1007\/s12325-024-02865-2","relation":{},"ISSN":["0741-238X","1865-8652"],"issn-type":[{"value":"0741-238X","type":"print"},{"value":"1865-8652","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,5,2]]},"assertion":[{"value":"8 February 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 April 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 May 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Christina Qian and Shelagh M Szabo are employees, and Evan Popoff was an employee, of Broadstreet HEOR, which received funds from Sarepta Therapeutics Inc for this work. Alexa C Klimchak and Katherine L Gooch are employees of Sarepta Therapeutics Inc. and may hold stock\/options. Susan T Iannaccone has received research funding or consulting fees from Avexis, Biogen, Fibrogen, Mallinckrodt, Regeneron, Sarepta, Scholar Rock, PTC Therapeutics, Pfizer, MDA, CureSMA, NIH, Genentech-Roche, and BCBS.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Data were provided by Merative\u2122, for access to a cut of data from the MarketScan<sup>\u00ae<\/sup> Multi-State Medicaid databases. Data are de-identified and are compliant with the Health Insurance Portability and Accountability Act (HIPAA) regulations; thus, institutional review board approval was not required to conduct this study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}